Products - Dementia | Topic | NICE

Showing 14 products

Date | Title

Suspected neurological conditions: recognition and referral (NG127)
Product type:
Guidance
Programme:
NICE guideline
Last updated:
2 October 2023
Published:
1 May 2019
Dementia: assessment, management and support for people living with dementia and their carers (NG97)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 June 2018
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (TA217)
Product type:
Guidance
Programme:
Technology appraisal guidance
Last updated:
20 June 2018
Published:
23 March 2011
Dementia, disability and frailty in later life – mid-life approaches to delay or prevent onset (NG16)
Product type:
Guidance
Programme:
NICE guideline
Published:
20 October 2015
Suspected neurological conditions: recognition and referral (QS198)
Product type:
Quality standard
Published:
8 January 2021
Dementia (QS184)
Product type:
Quality standard
Published:
28 June 2019
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease [ID4043]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
5 February 2025
Donanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID6222]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
26 March 2025
Hydromethylthionine mesylate for treating mild cognitive impairment or mild or moderate dementia caused by Alzheimer's disease [ID6343]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
30 April 2025
Prevention of dementia
Status:
Awaiting development
Expected publication date:
TBC
Gantenerumab for treating early Alzheimer's disease TS ID 10668
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Alzheimer's disease (early) - gantenerumab [ID6142]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Deep Brain Stimulation for Alzheimer
Status:
Topic selection
Programme:
Interventional procedures guidance
Expected publication date:
TBC
Pridopidine for treating Huntington's disease TSID 12052
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC